Ten research-grade peptides — each with a doctor-vetted summary of what published literature describes about mechanism, kinetics, and primary research. For qualified-researcher review only.
Triple-agonist (GIP / GLP-1 / Glucagon). Next-generation triple-agonist studied for appetite regulation and metabolic-pathway research.
Retatrutide (LY3437943) is a next-generation triple-agonist research peptide engineered to bind three incretin and glucose-regulating receptors simultaneously — GIP, GLP-1, and glucagon. By recruiting all three pathways at once, Retatrutide is one of the most pharmacologically distinct compounds currently being investigated in metabolic-pathway research.
Current investigational literature highlights Retatrutide's potency in pre-clinical and early clinical weight-management and metabolic studies, where the addition of glucagon-receptor activity is hypothesized to compound the energy-expenditure effects already established for GIP/GLP-1 dual-agonism.
Retatrutide functions as a balanced agonist across three receptor populations:
The combined-receptor profile differentiates Retatrutide from earlier mono- (GLP-1) and dual-agonist (GIP/GLP-1) research peptides.
Dual-agonist (GLP-1 / GIP). Dual-receptor research peptide investigated for appetite, glycemic, and metabolic-pathway studies.
Tirzepatide (LY3298176) is a dual-agonist research peptide targeting both the GLP-1 and GIP receptors. The dual-receptor mechanism is studied for its compounding effects on appetite signaling, gastric emptying, and post-prandial glucose regulation — and has driven significant body-weight reductions in published clinical-research settings.
Tirzepatide remains one of the most heavily-studied incretin-class research compounds and forms a reference point for newer multi-agonist peptides such as Retatrutide.
Tirzepatide engages two complementary incretin receptors:
The combined profile is studied for its capacity to amplify the metabolic effects of GLP-1 mono-agonism while reducing the GI-side-effect profile typically seen with high-dose GLP-1 alone.
GLP-1 receptor agonist. Long-acting GLP-1 analogue widely studied for appetite, satiety, and metabolic research.
Semaglutide is a long-acting GLP-1 receptor agonist research peptide and one of the most extensively studied incretin compounds in modern metabolic literature. As a structural analogue of native GLP-1, Semaglutide is engineered for prolonged plasma half-life and enhanced receptor affinity.
Research applications span appetite regulation, satiety modeling, gastric-emptying kinetics, and post-prandial glucose-handling — making it a foundational reference compound in any GLP-1 research workflow.
Semaglutide selectively activates the GLP-1 receptor, producing:
The Aib⁸ substitution and C18-diacid acylation extend half-life from minutes (native GLP-1) to roughly a week, making once-weekly research dosing feasible.
Body Protective Compound · pentadecapeptide. Gastric pentadecapeptide investigated for soft-tissue, gastric, and angiogenesis research.
BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide derived from a sequence identified in human gastric juice. It is one of the most widely cited research peptides in the soft-tissue and gastric-repair literature.
Preclinical work has explored BPC-157 across models of tendon, ligament, and gastrointestinal injury, with mechanisms broadly tied to angiogenesis, nitric-oxide signaling, and growth-factor expression.
BPC-157's reported activity in pre-clinical literature includes:
Stabilized GHRH (1-44) analogue. Stabilized GHRH analogue studied for somatotropic-axis and visceral-adiposity research.
Tesamorelin is a stabilized synthetic GHRH(1–44) analogue first characterized as TH9507. The N-terminal modification dramatically extends plasma half-life relative to native GHRH, enabling reproducible somatotropic-axis stimulation in research protocols.
Tesamorelin has been most heavily studied for its effects on the GH/IGF-1 axis and on visceral adipose tissue in HIV-associated lipodystrophy research.
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotrophs, driving pulsatile release of endogenous growth hormone. Downstream:
GHRH (1-29) amide. Truncated GHRH analogue studied for pulsatile GH release and recovery-pathway research.
Sermorelin is a 29-amino-acid amide corresponding to the active N-terminal fragment of native GHRH. It retains full GHRH-receptor binding activity in a more economical, easier-to-manufacture sequence than the full 44-residue parent peptide.
Sermorelin is widely used as a research benchmark for pulsatile somatotropic-axis stimulation and is frequently studied alongside Tesamorelin and CJC-1295 as part of GHRH-class investigations.
Sermorelin binds the GHRH receptor on pituitary somatotrophs, evoking a physiologic pulse of endogenous growth hormone — preserving the body's negative-feedback architecture, unlike exogenous GH administration. Downstream effects mirror native GHRH activity.
Cyclic α-MSH analogue. Cyclic heptapeptide studied for melanocortin-receptor pathways including pigmentation and libido.
Melanotan II (MT-II) is a cyclic synthetic analogue of α-MSH (alpha-melanocyte-stimulating hormone). The lactam bridge between Asp and Lys constrains the molecule into a bioactive conformation, increasing potency and proteolytic stability relative to linear α-MSH.
MT-II is studied across the melanocortin-receptor family — pigmentation pathways via MC1R, and central libido/arousal pathways via MC3R/MC4R.
MT-II is a non-selective agonist of the melanocortin-receptor family:
Mitochondrially-encoded peptide · 16 a.a.. Mitochondria-encoded peptide investigated for AMPK signaling and metabolic-resilience research.
MOTS-c is a small mitochondrially-encoded peptide derived from an open reading frame within the 12S rRNA gene. Unlike most peptides, it is translated from mitochondrial DNA — making it one of a small class of "mitochondrial-derived peptides" (MDPs) currently under longevity-research investigation.
Preclinical work has linked MOTS-c to AMPK activation, metabolic resilience, and exercise-mimetic signaling.
MOTS-c is reported to translocate from mitochondria to the nucleus under metabolic stress and to:
Copper-binding tripeptide. Naturally-occurring copper tripeptide investigated for collagen, hair, and skin-repair research.
GHK-Cu (Copper tripeptide-1) is a naturally-occurring tripeptide that binds Cu²⁺ with high affinity. Plasma concentrations of GHK decline measurably with age, and the compound has been studied extensively for its role in extracellular-matrix remodeling, wound-pathway research, and dermal-collagen signaling.
Of all the peptides in this catalog, GHK-Cu has one of the longest research literatures, dating back to the 1970s.
The GHK-Cu complex is reported to influence:
pH-buffered NAD+ coenzyme. pH-buffered redox cofactor investigated for mitochondrial-energy and sirtuin-pathway research.
NAD+ Buffered is a pH-stabilized formulation of nicotinamide adenine dinucleotide — a central redox coenzyme involved in nearly every catabolic pathway in human metabolism. Solvé's buffered form mitigates the well-known injection-site discomfort of acidic NAD+ preparations in research workflows.
NAD+ is studied for its role in mitochondrial-electron-transport function, sirtuin signaling, and the broader longevity literature.
Note — NAD+ is a coenzyme, not a peptide. It is included in our catalog because of its frequency in peptide-research workflows.
NAD+ functions as the universal electron acceptor in mitochondrial energy metabolism. It is also the obligate substrate for:
NAD+ tissue levels decline with age, motivating its inclusion in longevity-research stacks.
Members get every protocol, every COA, and the full reconstitution + tracker toolkit.